A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir in Orthotopic Liver Transplant Recipients
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Hepatitis C immune globulin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Biotest Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 30 Aug 2016 Status changed from active, no longer recruiting to completed.
- 15 Jan 2016 Planned End Date changed from 1 Oct 2015 to 1 May 2016 as reported by ClinicalTrials.gov.